SPTY2D1

Across TCGA pan-cancer cohorts, SPTY2D1 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated SPTY2D1 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher SPTY2D1 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated SPTY2D1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

UCEC, BRCA, and LIHC are the cancer types where SPTY2D1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.970	0.620	.003	32	view →
BRCA	OS	Median	III,IV	0.027	0.907	<.001	28	view →
LIHC	OS	Median	All	0.033	0.784	<.001	21	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
STAD	OS	Median	II,III,IV	1.000	0.404	.020	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUSC	OS	Median	All	0.173	0.724	.012	6	view →
COAD	DFS	Median	All	0.304	0.563	.034	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

SPTY2D1–UCEC (DFS)

Open the UCEC breakdown →